Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio

in Portfolio News

Eli Lilly is adding three new preclinical candidates to its immune and inflammatory medicines armory through TRexBio, a Bay Area biotech that specializes in T regulatory cells, or Tregs.

View the article
Investing in Women Code Logo

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.